StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Truist Securities Weighs in on Biogen (BIIB) Following 2nd Reported Alzheimer's Death
November 28, 2022 9:26 AM
Truist Securities analyst Robyn Karnauskas weighed in on Biogen (NASDAQ: BIIB) following recent news of the second death reported for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Trader Talk
Next Articles
Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
November 28, 2022 10:05 AM
Apple, Chevron, Biogen fall premarket; Univar, Pinduoduo rise
November 28, 2022 8:51 AM
Biogen (BIIB) on Watch Following Cautious Report in Science
November 28, 2022 7:13 AM